BI, MD Anderson Cancer Center Partner for Cancer Research and Virtual R&D Center
Boehringer Ingelheim (BI) and the University of Texas MD Anderson Cancer Center have formed a multi-year partnership to conduct collaborative research on therapies for various types of cancers, including the establishment of a joint Virtual Research and Development Center for data sharing and analysis between the organizations.
BI says the new Virtual Research and Development Center will focus on the development of potential new treatments, including KRAS inhibition concepts, as mutations in the KRAS gene are common in various cancers, specifically in certain types of lung and gastrointestinal cancers. It will also focus on TRAILR2 agonistic antibodies, which have the potential to selectively induce cancer cell death (apoptosis).
BI says the partnership is built on a flexible framework, allowing for projects to enter at different stages (research, development and/or clinical stage) over several years. It combines the drug-development capabilities of MD Anderson’s Therapeutic Discovery division with the pipeline of medicines from BI.
MD Anderson’s Therapeutics Discovery division is a multidisciplinary team of clinicians and researchers focused on cancer therapies. As part of the division, the Translational Research to Advance Therapeutics and Innovation in Oncology platform conducts translation research to better understand how new medicines work.
Source: Boehringer Ingelheim